Intravitreal dexamethasone implants for diabetic macular edema
Autor: | Virginia Lozano-López, Maribel Lopez-Galvez, Alicia Pareja-Ríos, Paloma Ruiz-de la Fuente-Rodríguez, Sergio Bonaque-González, Pedro Romero-Aroca |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
medicine.medical_specialty
retina genetic structures Diabetic macular edema dexamethasone Therapy naive 03 medical and health sciences 0302 clinical medicine lcsh:Ophthalmology Clinical Research Ophthalmology Diabetes mellitus medicine Dexamethasone medicine.diagnostic_test diabetes business.industry Single implant medicine.disease eye diseases Eye examination lcsh:RE1-994 Ozurdex 030221 ophthalmology & optometry Implant sense organs Outcome data business diabetic macular edema 030217 neurology & neurosurgery medicine.drug |
Zdroj: | International Journal of Ophthalmology, Vol 11, Iss 1, Pp 77-82 (2018) |
ISSN: | 2227-4898 2222-3959 |
Popis: | Aim To evaluate the safety and efficacy of a dexamethasone (DEX) intravitreal implant for diabetic macular edema (DME). Methods Totally 113 eyes of 84 patients were divided in three subgroups: naive patients (n=11), pseudophakic patients (n=72) and phakic patients (n=30). Inclusive criterion comprised adult diabetic patients with central fovea thickening and impaired visual acuity resulting from DME for whom previous standard treatments showed no improvement in both central macular thickness (CMT) and best corrected visual acuity (BCVA) after at least 3mo of treatment. Outcome data were obtained from patient visits at baseline and at months 1, 3, 5, 9 and 12 after the first DEX implant injection. At each of these visits, patients underwent measurement of BCVA, a complete eye examination and measurement of CMT and macular volume (MV) carried out with optical coherence tomography (OCT) images. Results Seventy-three eyes (64.5%) received a single implant, 30 (26.5%) received two implants and 10 (9%) received three implants. At baseline, average in BCVA, CMT and MV were 43.5±20.8, 462.8±145 and 12.6±2.5 respectively. These values improved significantly at 1mo (BCVA: 47.2±19.5, CMT: 339.6±120, MV: 11.11±1.4) and 3mo (BCVA: 53.2±18.1, CMT: 353.8±141, MV: 11.3±1.3) (P≤0.05). At 5mo (BCVA: 50.9±19.8, CMT: 425±150, MV: 12.27±2.3), 9mo (BCVA: 48.4±17.6, CMT: 445.5±170, MV: 12.5±2.3) and 12mo (BCVA: 47.7±18.8, CMT: 413.2±149, MV: 12.03±2.5), improvements in the three parameters were no longer statistically significant and decreased progressively but did not reach baseline values. There were no clinical differences between subgroups. Ocular complications were minimal. Conclusion Patients with DEX implants show maximum efficacy at 3mo which then declined progressively, but is still better than baseline values at the end of follow-up. |
Databáze: | OpenAIRE |
Externí odkaz: |